I WROTE A BOOK

NOW AVAILABLE FOR PRE-ORDER - "China Cure: The Rise of a Biotech, AI Medicine and Global Health Superpower"

Jul 30 • Ruby Wang

29

8

8

The China Decision Room: What Global Biopharma Companies Should Do – Franck Le Deu, Venture Partner at Aulis Capital & Sr Partner Emeritus…

The experienced health leader answers some of the biggest China strategy questions across global decision rooms today.

Jul 27 • Ruby Wang

10

1

4

1:06:23

June 2026

Inside China’s Health: On The Ground Across Six Provinces

Notes from my research trip, from Shenzhen factories and Chengdu AI adverts, to healthy-ageing policy meetings in Beijing and biotech conversations in…

Jun 5 • Ruby Wang

24

3

5

May 2026

The Politics of China's Health, At Home and Abroad - with Prof. Yanzhong Huang, Council on Foreign Relations

I chat with health security and governance expert, Prof Yanzhong Huang, on China’s health politics, US–China tensions and the transforming face of…

May 31 • Ruby Wang

12

4

3

49:46

March 2026

Doctor's Notes #6: A Spring Check-In from CHP

Recent reads, listens, and notes ahead of my April travels in China

Mar 24 • Ruby Wang

11

2

Investing in East-West Biotech: The 2026 State of Play - with China Biotech Dealmaker, Dr Leon Tang

A very timely behind-the-scenes breakdown, of the exciting investment and dealmaking landscape in China biotech.

Mar 8 • Ruby Wang

12

3

47:45

February 2026

Ant Afu: The Explosive Digital Health App Taking over China

My two cents on the seven-month-old AI app that already boasts 30 million monthly users and processes 10 million health queries per day.

Feb 18 • Ruby Wang

16

4

January 2026

Starmer in Beijing: Health, Science and Europe-China Relations - with Professor Kerry Brown

Looking beyond the headlines to examine the historical roots and future direction of the UK and Europe's engagement with China.

Jan 30 • Ruby Wang

8

4

46:43

Making Sense of China's Notorious National Drug Reimbursement List

What the recent publication of this high-stakes annual cycle revealed about how China prices risk, manages drug access and controls access to health…

Jan 20 • Ruby Wang

11

1

2

Scaling a Leading Global Biotech from China - with Josh Smiley, President and COO of Zai Lab

A exclusive insider's view on the trajectory of China’s booming biotech sector, from one of the industry’s most senior global operators.

Jan 5 • Ruby Wang

14

7

57:22

December 2025

China’s Health Ministries (Pt. 3): Who Controls the Money – and Why the NHSA Matters Most

An essential guide to the National Healthcare Security Administration - the gatekeeper of market access, at the hardest edge of China’s health system.

Dec 26, 2025 • Ruby Wang

13

5

China Health Pulse: 2025 Wrapped

Doctor's Notes #5: Reflecting on an extraordinary year for the CHP newsletter.

Dec 17, 2025 • Ruby Wang

9